Recs

19

The 10 Best Stocks You Might Actually Buy

I'm easily obsessed by what I read. Too much Tom Wolfe and my sentences are paragraph-length head trips. If my bedtime stories come from Stephen King, it'll be a week of sewer-dwelling monster-clowns and the "coppery taste of blood and fear" on the back of my tongue.

Recently, I became obsessed with something a bit less frightening. In fact, it's downright uplifting. I'm talking about the numbers in Jeremy Siegel's book The Future for Investors. In it, the man who's credited with "calling the top" of the Internet bubble -- the timing of which he maintains was luck -- demolishes many of the investing tropes that lose us all time and money.

One of the myths he buries is that you need obscure, unheard-of stocks to trounce the wider market. This is simply not true. And that's especially good news, I think, because I have grave doubts about whether any of us can actually find the next big thing. Don't get me wrong -- I want to find it, too, but I'm a realist, and I think my odds of catching that train are low.

Siegel's wide-ranging analysis only reinforces that suspicion, scuttling the idea that blindly chasing growth -- in hopes that one or two big winners can make up for a pile of big risks -- will make you wealthy. (Turns out, when you toss a pile of spaghetti against the wall to see what sticks, most of it really does land on the floor. The one or two noodles that remain will not provide a meal.)

Here's the most simple, powerful, takeaway from Siegel's work: You don't have to look under rocks to find stocks that deliver rock-solid returns.

It's possible to generate market-beating gains with reliable, well-known companies, the kind of stocks you might actually buy, companies that won't give you an ulcer. Let's go to his numbers. These are the top 10 "survivor" stocks of the original S&P 500, from inception until post-2000, with their average annual returns.

Company

Annual Return

Average P/E

Altria

19.8%

13.1

Abbott Laboratories (NYSE:ABT)

16.5%

21.4

Bristol-Myers Squibb (NYSE:BMY)

16.4%

23.5

Tootsie Roll Industries

16.1%

16.8

Pfizer

16.0%

26.2

Coca-Cola (NYSE:KO)

16.0%

27.4

Merck (NYSE:MRK)

15.9%

25.3

PepsiCo

15.5%

20.4

Colgate-Palmolive (NYSE:CL)

15.2%

21.6

Crane (NYSE:CR)

15.1%

13.4

Source: Jeremy Siegel, The Future for Investors.

I find this list incredible, because it shows the power of investing in well-known companies. None of these firms was a newcomer back in the 1950s. In fact, many of them were already decades old and world-famous when the index was created. Yet they all provided market-whomping returns. How is that possible?

Here's the secret: Those returns are calculated with dividends reinvested. In fact, as Siegel later explains, a healthy dividend, regularly redeployed, is the key to compounding average returns into long term, market-beating gains.

This makes perfect sense. When strong companies suffer a down market, those dividends buy you more shares. When the markets readjust, you reap the rewards on more shares.

The longer I invest, the more I find myself adding these kinds of companies to my portfolio. Of course, being a value type, I try to buy them when they're cheapest, but I'm not afraid to pay up for quality. As the third column in that table shows, premium companies always demand a bit of a premium price in the market.

The lesson looks clear enough to me. Boring, already-well-known dividend payers can power your returns for decades. You don't have to give up your search for the next big thing, but keeping a strong portfolio foundation with stocks like these is the smartest way to play.

Their track record for performance makes them perfect for your tax-free retirement accounts and, as my colleague Robert Brokamp has discussed in his Motley Fool Rule Your Retirement service, a large stable of dividend payers means income without stock sales. (Let's face it, the best way to heat your house is not to burn the furniture.)

If you'd like to learn more about how dividend-payers like these can help you retire in style, a 30-day guest pass to Rule Your Retirement is free. There's even a featured interview with Jeremy Siegel, where you can learn more about his research.

This article was originally published March 10, 2006. It has been updated.

Seth Jayson likes to see that cash. At the time of publication, he had no positions in any company mentioned here. View his stock holdings and Fool profile here. Coke, Pfizer, and Colgate-Palmolive are Motley Fool Inside Value recommendations. Pfizer is also an Income Investor pick. Fool rules are here.


Read/Post Comments (0) | Recommend This Article (19)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 605343, ~/Articles/ArticleHandler.aspx, 4/23/2014 5:39:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Seth Jayson
TMFBent

Today's Market

updated 8 hours ago Sponsored by:
DOW 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASD 4,161.46 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/22/2014 4:02 PM
ABT $38.60 Down -0.11 -0.28%
Abbott Laboratorie… CAPS Rating: *****
BMY $50.99 Up +0.48 +0.95%
Bristol-Myers Squi… CAPS Rating: ****
CL $66.36 Down -0.48 -0.72%
Colgate-Palmolive CAPS Rating: *****
CR $71.77 Up +0.35 +0.49%
Crane Co. CAPS Rating: *****
KO $40.71 Down -0.04 -0.10%
Coca-Cola CAPS Rating: ****
MRK $57.77 Up +0.52 +0.91%
Merck & Co., Inc. CAPS Rating: ***

Special Offer for Savvy Investors Like You!

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut semper dui vitae molestie venenatis. Suspendisse.

Enter Email Address:



Privacy / Legal Information
Advertisement